Page 11234

Category Archives: Ventricular Remodeling

BioVentrix Announces Publication of Positive One-Year Outcomes for Revivent TC System – Yahoo Finance

Posted: December 4, 2019 at 3:41 pm

Study Published in European Journal of Heart Failure Shows Significant and Sustained Improvement in Heart Function, Symptom Relief and Quality of Life Using Less Invasive Left Ventricular Enhancement Device BioVentrix, Inc., developer of the first less invasive system for left ventricular remodeling, today announced online publication of positive one-year results from its CE Mark study of the Revivent TC System in the European Journal of Heart Failure. The paper will be published in print in the January issue of the journal. Authors of the study, entitled "Less Invasive Ventricular Reconstruction for Ischemic Heart Failure" concluded, "Treatment with the Revivent TC System in patients with symptomatic heart failure results in significant and sustained reduction of left ventricular (LV) volumes and improvement of LV function, symptoms, and quality of life." They added, "The ability to achieve these results without the need for sternotomy or cardiopulmonary bypass is an important advance for the treatment of patients suffering from ischemic cardiomyopathy heart failure." The prospective, multicenter, single-arm study of 89 patients at 22 centers in 12 countries in the European Union was designed to evaluate the efficacy and safety of the Revivent TC System for scar exclusion in the heart, volume reduction, and reshaping of the LV in selected patients with ischemic cardiomyopathy (enlarged and weakened left ventricle with reduced capacity to pump blood after a heart attack) Continue reading

Posted in Ventricular Remodeling | Comments Off on BioVentrix Announces Publication of Positive One-Year Outcomes for Revivent TC System – Yahoo Finance

Patients With Chemotherapy-Induced Cardiomyopathy Show Improvements in LVEF After Cardiac Resynchronization Therapy – AJMC.com Managed Markets Network

Posted: at 3:41 pm

Maggie L. Shaw Heart issues in patients with cancer and survivors can present themselves months or years after treatment Continue reading

Posted in Ventricular Remodeling | Comments Off on Patients With Chemotherapy-Induced Cardiomyopathy Show Improvements in LVEF After Cardiac Resynchronization Therapy – AJMC.com Managed Markets Network

Pulmonary Hypertension, Common in TAVR Patients, Linked to Lower Survival – TCTMD

Posted: December 3, 2019 at 7:44 am

LONDON, EnglandPatients with pulmonary hypertension (PH) undergoing TAVR for severe symptomatic aortic stenosis fare significantly worse than those without increased pre-interventional pulmonary pressures, a new analysis shows. After a mean follow-up of 31 months, patients with PH, which was defined as a mean pulmonary arterial pressure (mPAP) > 25 mm Hg, had a 60% increased risk of all-cause mortality compared with those without PH, reported Dionysios Adamopoulos, MD (Geneva University Hospital, Switzerland), last week at PCR London Valves 2019. Continue reading

Posted in Ventricular Remodeling | Comments Off on Pulmonary Hypertension, Common in TAVR Patients, Linked to Lower Survival – TCTMD

3 Stocks to Buy Ahead of the Next Market Crash – The Motley Fool

Posted: at 7:44 am

No one knows when the next market crash is coming. Continue reading

Posted in Ventricular Remodeling | Comments Off on 3 Stocks to Buy Ahead of the Next Market Crash – The Motley Fool

Velocity Transfer Function In The Right Pulmonary Artery And Impaired | COPD – Dove Medical Press

Posted: at 7:44 am

Oleg F Sharifov,1 Thomas S Denney Jr,2 J Michael Wells,1,3,4 Gregory A Payne,1,4 Swati Gulati,1,3 Himanshu Gupta,5 Mark T Dransfield,1,3,4 Steven G Lloyd1,4 1Department of Medicine, University of Alabama at Birmingham (UAB), Birmingham, AL, USA; 2Department of Electrical and Computer Engineering, Auburn University, Auburn, AL, USA; 3UAB Lung Health Center, Birmingham, AL, USA; 4Birmingham VA Medical Center, Birmingham, AL, USA; 5Advanced Cardiovascular Imaging, Valley Medical Group, Paramus, NJ, USA Correspondence: Steven G Lloyd Department of Medicine, University of Alabama at Birmingham, 1808 7th Avenue South, BDB 201, Birmingham, AL 35294-0012, USA Tel +1 205 934 9736 Fax +1 205 934 9730 Email slloyd@uabmc.edu Pulmonary hypertension (PH) is an important prognostic indicator in patients with chronic obstructive pulmonary disease (COPD); however, PH in these patients is typically mild-to-moderate severity and invasive testing is not typically utilized.1 Though echocardiography can be used to screen for PH, it has limited accuracy in measuring pulmonary artery (PA) pressure and often hindered by window limitations in COPD patients.2 Cardiovascular magnetic resonance (CMR) does not have window limitations and can accurately evaluate the right ventricular (RV) and PA function. Therefore, there is a growing interest in the use of CMR for the diagnosis and management of PH, including patients with lung diseases Continue reading

Posted in Ventricular Remodeling | Comments Off on Velocity Transfer Function In The Right Pulmonary Artery And Impaired | COPD – Dove Medical Press

Cardiac Restoration Systems Market: Key Growth Factors and Industry Analysis 2018 – 2028 – The Market Expedition

Posted: at 7:44 am

TMRR, in its recent market report, suggests that the Cardiac Restoration Systems market report is set to exceed US$ xx Mn/Bn by 2029. The report finds that the Cardiac Restoration Systems market registered ~US$ xx Mn/Bn in 2018 and is spectated to grow at a healthy CAGR over the foreseeable period. This Cardiac Restoration Systems market study considers 2018 as the base year, 2019 as the estimated year, and 2019 2029 as the forecast timeframe. Continue reading

Posted in Ventricular Remodeling | Comments Off on Cardiac Restoration Systems Market: Key Growth Factors and Industry Analysis 2018 – 2028 – The Market Expedition

Edited Transcript of MYOK earnings conference call or presentation 11-Nov-19 1:30pm GMT – Yahoo Finance

Posted: at 7:44 am

SOUTH SAN FRANCISCO Dec 2, 2019 (Thomson StreetEvents) -- Edited Transcript of MyoKardia Inc earnings conference call or presentation Monday, November 11, 2019 at 1:30:00pm GMT MyoKardia, Inc. - SVP of Clinical Development MyoKardia, Inc. - SVP of Medical Sciences MyoKardia, Inc. Continue reading

Posted in Ventricular Remodeling | Comments Off on Edited Transcript of MYOK earnings conference call or presentation 11-Nov-19 1:30pm GMT – Yahoo Finance

Contrasting of BioLineRx Ltd. (BLRX) and Moderna Inc. (NASDAQ:MRNA) – The Broch Herald

Posted: at 7:44 am

As Biotechnology businesses, BioLineRx Ltd. (NASDAQ:BLRX) and Moderna Inc. (NASDAQ:MRNA), are affected by compare. Continue reading

Posted in Ventricular Remodeling | Comments Off on Contrasting of BioLineRx Ltd. (BLRX) and Moderna Inc. (NASDAQ:MRNA) – The Broch Herald

Triple-Gene Announces Completion of Enrollment and Dosing in Phase 1 Trial of INXN-4001, First Multigenic Investigational Therapeutic Candidate for…

Posted: November 7, 2019 at 9:43 pm

GERMANTOWN, Md., Nov. 7, 2019 /PRNewswire/ -- Triple-Gene LLC, a clinical stage cardiovascular gene therapy company and majority owned subsidiary of Intrexon Corporation (NASDAQ: XON), today announced the completion of enrollment and dosing in its Phase 1 trial of INXN-4001, a multigenic investigational therapeutic candidate under evaluation for the treatment of heart failure, the leading cause of death worldwide. The Phase 1 open label study is designed to investigate the safety of INXN-4001 delivered via Retrograde Coronary Sinus Infusion (RCSI) in patients with an implanted Left Ventricular Assist Device (LVAD) for mechanical support of end-stage heart failure, either as a bridge to transplant or destination therapy (clinical trial identifier: NCT03409627) Continue reading

Posted in Ventricular Remodeling | Comments Off on Triple-Gene Announces Completion of Enrollment and Dosing in Phase 1 Trial of INXN-4001, First Multigenic Investigational Therapeutic Candidate for…

BioLineRx Ltd. (BLRX)’s Financial Results Comparing With Cyanotech Corporation (NASDAQ:CYAN) – The Broch Herald

Posted: at 9:43 pm

BioLineRx Ltd. (NASDAQ:BLRX) and Cyanotech Corporation (NASDAQ:CYAN) are two firms in the Biotechnology that compete against each other Continue reading

Posted in Ventricular Remodeling | Comments Off on BioLineRx Ltd. (BLRX)’s Financial Results Comparing With Cyanotech Corporation (NASDAQ:CYAN) – The Broch Herald

Page 11234